期刊文献+

复发性外阴阴道念珠菌病的预防性治疗观察 被引量:6

Observation of Treatment of Recurrent Vulvovaginal Caudidiasis
下载PDF
导出
摘要 目的:探讨复发性外阴阴道念珠菌病(RVVC)的预防性治疗效果。方法:将复发性外阴阴道念珠菌病患者59例随机分成两组,A组27例,为对照组,给伊曲康唑200mg,餐后口服,2次/d,连服2d,同时每晚阴道给药达克宁栓200mg/粒置于阴道后穹窿,连续7d。B组32例,为观察组,开始7d用药同A组,以后于每次月经干净的d1和d2餐后口服伊曲康唑200mg,每天2次,连续用药6个月。结果:A、B两组在开始治疗7d后,治愈率分别为92.59%和93.75%,差异无显著性(X2=0.0312,P>0.05);治疗3个月、6个月、12个月各阶段的复发率分别为A组20%、36%、48%,B组0、3.33%、6.67%,两组有显著性差异(X2值分别为6.599、9.785、12.275,P值分别为<0.05、<0.01、<0.001)。结论:伊曲康唑预防性治疗能有效地阻止RVVC的复发。 Objective: To explore the effect of prophylactic treatment on recurrent vulvovaginal caudidiasis ( RWC ). Method: 59 patients with RVVC were divided randomly into two groups. 27 cases of group A ( contrast group ) were given Iraconazole ( tablet ) 200 mg p. c bid for 2 days, meanwhile Miconanole ( suppository) 1 sup ( 200 mg) bury into the hack fomix of vagina every night for 7 days. 32 cases of group B ( treatment group ) were the same medication as group A at the first 7 days, then Iraconazole 200 mg p. c bid at the first 2 days after menses for6 months. Result: Cure rate of the first 7 days treatment :group A was 92.59%, group B was 93.75%, the difference isnt notable ( X^2 = 0. 0312, P 〉 0.05 ) ; Relapse rates of the 3,6,12 month were group A 20% ,36% ,48% and group B 0.00% ,3.33% ,6.67% ,the difference is notable ( X^2 = 6.599,9. 785,12.275, P 〈 0.05, 〈 0.01, 〈 0.001 ). Conclusion: Prophylactic treatment by Iraconazole can prevent the relapse of RWC efficiently.
作者 孙哲琦
出处 《河北医学》 CAS 2006年第8期777-779,共3页 Hebei Medicine
关键词 复发性外阴阴道念珠菌病 预防性治疗 伊曲康唑 Recurrent vulvovaginal caudidiasis Prophylactic treatment Itraconazole
  • 相关文献

参考文献1

二级参考文献18

  • 1Fidel PL Jr, Lynch ME, Sobel JD. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis.Infect Immun, 1993,61 (5): 1990 - 1995.
  • 2Fidel PL Jr, Lynch ME, Sobel JD. Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect Immun, 1994,62 (3): 1032 - 1038.
  • 3Fidel PL Jr, Lynch ME, Sobel JD. Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. Infect Immun, 1995,63 (7) :2403 - 2408.
  • 4Cantoma M, Mook D, Balish E. Resistance of congenitally immunodeficient gnotobiotic mice to vaginal candidiasis. Infect Immun, 1990,58(11) :3813 -3815.
  • 5Fidel PL Jr, Lynch ME, Conaway DH, et al. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun, 1995, 63(2) :547 -553.
  • 6Taylor BN, Saavedra M, Fidel PL Jr. Local Thl/Th2 cytokine production during experimental vaginal candidiasis: potential importance of transforming growth factor-beta. Med Mycol, 2000, 38 (6):419 -431.
  • 7Saavedra M, Taylor B, Lukacs N, et al. Local production of chemokines during experimental vaginal candidiasis. Infect Immun, 1999,67(11):5820-5826.
  • 8Wormley FL Jr, Chalban J, Fidel PL Jr. Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis. Infect Immun, 2001,69(8):5072 - 5079.
  • 9Polonelli L, De Bernardis F, Conti S, et al. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol, 1994, 152(6): 3175-3182.
  • 10de Bernardis F, Santoni G, Boccanera M, et al. Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans. Infect Immun, 2000, 68(6) :3297 -3304.

共引文献11

同被引文献32

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部